London, UK, 23 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces ...
Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ ...
Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to ...
BASEL, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of ...
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s ...
A new research project aims to develop the world’s first therapy to eliminate and prevent the spread of a toxic brain protein that drives Parkinson’s disease. Innovation Fund Denmark has invested DKK ...
Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting.
CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), today announced it has entered into a definitive asset purchase ...
Presented by CEO Dave Marver, the webcast will be held at 2:00 p.m. CEST / 08:00 a.m. ET. To join the session, please register using this link.
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with ...
INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia
The direct advertiser and wellness infrastructure company targets five new countries as global wellness demand accelerates in emerging markets. BERLIN, March 22, 2026 (GLOBE NEWSW ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results